Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if diagnosed early.

An experimental drug has successfully slowed the progress of amyotrophic lateral sclerosis in a phase 2 study, its developer announced on Tuesday. Participants taking AMX0035, designed to reduce ...

ALS is a progressive disease, meaning it worsens over time. Although there is no cure for ALS, medications and therapies are available to help manage the symptoms, slow the disease course, and prolong ...

Scientists invented a pocket-sized model of the most common form of amyotrophic lateral sclerosis (ALS). The "disease-on-a-chip," made using stem cells, could pave the way for new treatments for the ...

Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral ...

Neuroscientists at Macquarie University in Australia have developed a single-dose genetic medicine that has been proven to halt the progression of both ALS and frontotemporal dementia (FTD) in mice – ...

Amyotrophic lateral sclerosis (ALS) is a condition that causes the degeneration of the nerve cells in the nervous system, affecting certain neurons in the spinal cord. ALS is a fatal disease that ...

The MarketWatch News Department was not involved in the creation of this content. This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to ...

Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...

A stem-cell-based "organ-on-a-chip" model of ALS mimics early biological changes seen in the degenerative disease. When you purchase through links on our site, we may earn an affiliate commission.